Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Zydus Cadila gets...

    Zydus Cadila gets tentative USFDA nod to Lacosamide tablets to treat seizures

    Farhat NasimWritten by Farhat Nasim Published On 2019-04-08T10:00:38+05:30  |  Updated On 13 Aug 2021 4:26 PM IST

    Lacosamide is an anti convulsant or anti-epileptic drug, used to prevent and control seizures. It works by reducing the spread of seizure activity in the brain.


    New Delhi: Drug firm ZydusCadila Monday said it has received a tentative nod from the US health regulator for marketing generic Lacosamide tablets, used for prevention and treatment of seizures, in the American market.


    The company has received the tentative approval from the United States Food and Drug Administration (USFDA) to market generic Lacosamide tablets in the strengths of 50 mg, 100 mg, 150 mg and 200 mg, Zydus Cadila said in a statement.


    The product is a generic version of Vimpat tablets, it added.

    Also Read: Zydus Cadila gets tentative USFDA nod to Tofacitinib tablets for treating arthritis


    "The drug will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad," Zydus Cadila said.


    Lacosamide is an anti-convulsant or anti-epileptic drug, used to prevent and control seizures. It works by reducing the spread of seizure activity in the brain, it added.

    The group now has 261 approvals and has so far filed over 350 abbreviated new drug applications (ANDAs) since the commencement of its filing process, Zydus Cadila said.

    Shares of Cadila Healthcare, the listed entity of the group, were trading at Rs 346.15 per scrip on the BSE, up 0.41 per cent from its previous close.

    Also Read: Zydus Cadila gets tentative USFDA nod for Mirabegron ER tablets to treat overactive bladder

    anti-epileptic drugepileptic druggenericLacosamideLacosamide tabletspharma newspharma news indiaseizuresUS marketUSFDAzydusZydus CadilaZydus Moraiya
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok